
Opinion|Videos|May 14, 2025
Common Causes of Bronchiectasis
Panelists discuss how evaluating potential causes of bronchiectasis is important despite many cases being idiopathic, as identifying treatable traits can lead to specific interventions, such as CFTR modulators for those with CF mutations or IgG supplementation.
Advertisement
Episodes in this series

Clinical Brief: Etiologic Evaluation and First-Line Treatment of Bronchiectasis
Main Discussion Topics
- Etiologic evaluation is important, though many cases remain idiopathic.
- Treatment follows both “one-size-fits-all” baseline approaches and targeted interventions based on identified causes.
- First-line treatments focus on airway clearance, hydration, and infection management.
Key Points for Physicians
- Universal approaches include:
- Airway clearance techniques
- Physical exercise/pulmonary rehabilitation
- Regular clinical follow-up
- Nutritional counseling
- Vaccinations
- Etiologic evaluation may identify treatable traits:
- CFTR mutations (potential for modulators)
- Low IgG (consider supplementation)
- Aspiration/reflux (specific management)
- Sinus disease (targeted treatment)
- Personalize approaches based on the patient’s specific presentation and underlying etiology.
Notable Insights
In approximately 40% to 50% of cases, etiologic evaluation can identify host susceptibility factors that allow for targeted interventions beyond general management.
Clinical Significance
Combining universal bronchiectasis management approaches with etiology-specific interventions creates a more effective personalized treatment strategy.
Advertisement
Related to this article

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.

Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.

Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.

The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
2
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
3
5 Things to Know About Diabetes-Related Eye Disease Awareness Month
4
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
5

